CRBP — Corbus Pharmaceuticals Holdings Share News
0.000.00%
Last trade - 00:00Corbus Pharma doubles as cancer therapy shows promise in early-stage trial
Brief: Corbus Pharmaceuticals Says CRB-701 Was Well-Tolerated In First-In-Human Study
Brief: Corbus Pharmaceuticals Announces FDA Clearance Of Ind Application For Its Anti-Αvβ8 Monoclonal Antibody (Crb-601)
Brief: Corbus Pharmaceuticals Holdings Says On Nov 10, Got Letter From Nasdaq Indicating Co Was Not In Compliance With Minimum Stockholders’ Equity Requirement
Corbus Pharmaceuticals Holdings Inc expected to post a loss of $2.06 a share - Earnings Preview
Brief: Corbus Pharmaceuticals Presents Results Of Two Pre-Clinical Studies
Brief: Corbus Pharmaceuticals Announces Publication Of Data For Its Novel Cannabinoid Type-1 Receptor Inverse Agonist
Brief: Corbus Pharmaceuticals Presents The First Pre-Clinical Characterization Of Its Next Generation Nectin-4 ADC CRB-701
Corbus Pharmaceuticals Holdings Inc reports results for the quarter ended in June - Earnings Summary
Brief: Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results And Provides Corporate Update
Corbus Pharmaceuticals Holdings Inc expected to post a loss of $3.10 a share - Earnings Preview
Brief: Corbus Pharmaceuticals Set To Join Russell Microcap® Index
Brief: Corbus Pharmaceuticals Enters Into Open Market Sale Agreement With Jefferies
Brief: Corbus Pharmaceuticals Holdings Inc Files For Mixed Shelf Of Up To $100 Mln - SEC Filing
Corbus Pharmaceuticals Holdings Inc reports results for the quarter ended in March - Earnings Summary
Brief: Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results And Provides Corporate Update
Corbus Pharmaceuticals Holdings Inc expected to post a loss of $4.09 a share - Earnings Preview
Brief: Corbus Pharmaceuticals Presents Latest Pre-Clinical Data On Crb-601
Brief: Corbus Pharmaceuticals Data On Crb-601 Avβ8 Blocking Antibody Accepted For Presentation At The America Association For Cancer Research Annual Meeting